Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
It is not individualized medical advice and does not recommend dosing, self-experimentation, or unsupervised medication changes
Each organ has unique metabolic demands and pathways that can be dysregulated in cancer, leading to distinct metabolic profiles for different types of tumors
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
Our goal at Rivas Medical Weight Loss is to provide our patients with the tools and information to achieve a reduced weight and maintain the loss long term
Can polymers benefit from melting point determination
US$ 27.71
US$ 27.64
US$ 22.94
US$ 23.91
US$ 20.87
US$ 28.48
US$ 29.06
US$ 25.42
